The objective of this pilot study is to examine proteomic features and biological differences in CBF and non-CBF pediatric AML, as well as to uncover proteomic markers that are associated with the therapeutic responses through minimal residual disease post first induction (MRD1) and in vitro leukemic cell cytarabine chemosensitivity (Ara-C LC50). Here, CEBPZ is linked to acute myeloid leukemia.